Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Childhood Myelodysplastic Neoplasms

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Myelodysplastic Neoplasms in children and adolescents

Source population
pediatric
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      clinically-proposed
      derivation note
      Derived from NCI topic(s): Childhood Myelodysplastic Neoplasms. Strongest NCIt resolution: candidate. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null

      Study evidence for this setting

      0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2025-01-21 · treosulfan with fludarabine · approval notification
      release id
      clinical-indications-draft-1
      disease state id
      ds-myelodysplastic-neoplasms-pediatric
      event id
      notice-5dc558910cebfff0
      event date
      2025-01-21
      event kind
      approval-notification
      drug or regimen
      treosulfan with fludarabine
      source indication text
      FDA approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome .
      match phrase
      myelodysplastic syndrome
      match status
      candidate
      status category
      Source null
      has date discrepancy
      0
      source collection
      fda-approval-notice
      source key
      fda-eed3ef224dcd705a
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-myelodysplastic-neoplasms-pediatric
        binding id
        ncit-C3247
        source collection
        ncit-concept
        source key
        C3247
        source excerpt
        Source null
        match status
        candidate
        match note
        Resolution status: candidate.
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice